Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among gram-negative bacilli: Need for international harmonization in terminology

Clinical Infectious Diseases

Volumn 46, Issue 7, 2008, Pages 1121-1122

  Falagas, Matthew E ^a,b   Karageorgopoulos, Drosos E ^a  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; LETTER; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; TERMINOLOGY AS TOPIC;

EID: 42549104674     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/528867     Document Type: Letter

References (11)

1. Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45:1179-81.
2. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
3. Hoban DJ, Bouchillon SK, Dowzicky MJ. Antimicrobial susceptibility of extended-spectrum β-lactamase producers and multidrug-resistant Acinetobacter baumannii throughout the United States and comparative in vitro activity of tigecycline, a new glycylcycline antimicrobial. Diagn Microbiol Infect Dis 2007; 57:423-8.
4. Falagas ME, Koletsi PK, Bliziotis IA. The diversity of definitions of multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006; 55:1619-29.
5. Merriam-Webster Online Dictionary. 2005. Available at: http://www.merriam-webster.com/. Accessed 10 October 2007.
6. Dorland's Illustrated Medical Dictionary, 30th ed. Philadelphia: WB Saunders, 2003.
7. Falagas ME, Bliziotis IA, Kasiakou SK, Samonis G, Athanassopoulou P, Michalopoulos A. Outcome of infections due to pandrug-resistant (PDR) gram-negative bacteria. BMC Infect Dis 2005; 5:24.
8. Falagas ME, Kasiakou SK. Correct use of the term "pan-drug- resistant" (PDR) gram-negative bacteria. Clin Microbiol Infect 2005; 11:1049-50.
9. Kern DH, Weisenthal LM. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures. J Natl Cancer Inst 1990; 82:582-8.
10. Extensively drug-resistant tuberculosis (XDR-TB): recommendations for prevention and control. Wkly Epidemiol Rec 2006; 81:430-2.
11. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43(Suppl 2):43-8.